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Abstract
Microarray studies with human subjects often have limited sample sizes which hampers the ability to detect reliable
biomarkers associated with disease and motivates the need to aggregate data across studies. However, human gene
expression measurements may be influenced by many non-random factors such as genetics, sample preparations, and
tissue heterogeneity. These factors can contribute to a lack of agreement among related studies, limiting the utility of their
aggregation. We show that it is feasible to carry out an automatic correction of individual datasets to reduce the effect of
such ‘latent variables’ (without prior knowledge of the variables) in such a way that datasets addressing the same condition
show better agreement once each is corrected. We build our approach on the method of surrogate variable analysis but we
demonstrate that the original algorithm is unsuitable for the analysis of human tissue samples that are mixtures of different
cell types. We propose a modification to SVA that is crucial to obtaining the improvement in agreement that we observe.
We develop our method on a compendium of multiple sclerosis data and verify it on an independent compendium of
Parkinson’s disease datasets. In both cases, we show that our method is able to improve agreement across varying study
designs, platforms, and tissues. This approach has the potential for wide applicability to any field where lack of inter-study
agreement has been a concern.
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Introduction
Microarray based expression profiling is widely used to
investigate molecular changes associated with disease states and
has the potential to elucidate clinically useful biomarkers that can
be used for diagnosis, monitoring or personalized treatment. Since
studies with human subjects often have limited size, meta-analysis
methods that seek to improve the detection of differentially
expressed genes through aggregation have received considerable
attention. The varying approaches include explicit parametric
models of error in gene expression measurements [1–4], heuristic
aggregation of top differentially expressed genes [5],and using
literature derived knowledge to find common network based
patterns [6–8]. However, a key question that is typically not
addressed in these methods is how to deal with studies that
produce discordant results despite addressing similar biological
questions. A lack of inter-study concordance is a common finding
in human datasets [8–10], and it is well established that combining
disagreeing or outlier studies can reduce the statistical power as
well as lead to erroneous conclusions [11–14]. This becomes a
problem of increasing concern as meta-analysis efforts are scaled
up via searchable databases that allow biologists and clinicians to
aggregate differentially expressed genes across related studies
without carrying out explicit statistical analysis [15,16].
Multiple sclerosis (MS) is a relatively common autoimmune
disease that provides an informative case study in biomarker
discovery and validation. Heterogeneity of clinical subtypes,
episodes of relapse and remission, and varying response to
treatment make the progression of the disease unpredictable and
difficult to evaluate [17]. For that reason, there is considerable
interest in the establishment of reliable molecular biomarkers that
can be used to diagnose and monitor the disease. To improve our
understanding of the molecular mechanisms involved, a number of
microarray studies comparing various clinical groups have been
undertaken. While many of the studies produce intriguing results
on the nature of immune dysregulation [18–27], most findings
have not been confirmed in independent studies, and MS
biomarker discovery has been hampered by this lack of
reproducibility. For example, the report that IL17F serum
concentration was predictive of a lack of response to interferon
therapy [28] was not confirmed by a subsequent study [29]. Meta-
analytic approaches that combine data from different studies have
the potential to elucidate biomarkers that are more likely to
capture the underlying disease biology rather than differences
limited to the specific patient cohort.
In this study, we demonstrate a novel statistically based
approach to meta-analysis using a compendium of publicly
available studies. Rather than simply aggregating the datasets for
greater statistical power, we propose a method that improves inter-
study agreement by applying an automated statistical correction to
datasets on an individual basis. Our approach is based on the
method of Surrogate Variable Analysis (SVA) [30] which uses the
correlation structure of each dataset to estimate and correct for
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latent sources of variation. However, we demonstrate that the
correlation structure of human disease studies may deviate
considerably from the assumptions underlying SVA and propose
an alternative approach that is essential to producing the improved
agreement we observe. We demonstrate that the modified method
improves agreement in our MS compendium and we verify this
effect in an independent set of Parkinson’s disease datasets. While
it is often possible to extract more meaningful information from
individual datasets by applying ad hoc analysis methods, we
demonstrate that latent variable correction is a generalizable
approach that can be applied in bulk to public datasets to achieve
improved results.
Results
The fundamental underlying assumption of MS biomarker
studies is that there is a disease associated neuroinflammatory
signature that can be observed in gene expression measurements.
In principle, meta-analysis should be able to elucidate genes that
may not be the top differentially expressed candidates in any one
study, but that are nevertheless reproducibly changed across
multiple expression profiles and are thus more likely to be related
to the underlying disease process.
The current understanding of disease pathology is that it
involves the infiltration of CNS tissue by blood derived leukocytes,
and existing therapies target either immune cell activation or
blood-brain permeability [31], suggesting that aberrant regulation
of these processes should be detectable at the molecular level. In
order to evaluate whether a common molecular signature can be
observed in gene expression measurements of multiple sclerosis
patients, we compiled a compendium of publicly available multiple
sclerosis datasets (Table 1). While the complexity of this disease has
led to studies of varying designs, all the studies in our compendium
aim to evaluate patient groups with different multiple sclerosis
phenotypes, and molecular changes that segregate these groups
should in principle reflect the underlying neuroinflammatory
process.
Multiple sclerosis studies have low agreement
In order to accommodate studies with multi-group designs, we
employ analysis of variance for determining differential expression,
a technique that has been previously used in a multi-group meta
analysis setting [32]. We expect that the number of reproducibly
altered genes to be small and in order to quantify the extent of
non-random overlap in differential expression ranking within our
compendium we follow the ‘‘concordance at the top’’ approach
proposed in [33]. We select the top 5% of the genes in each dataset
and score the overlap between all pairs of datasets using a
hypergeometric test.
The hypergeometric test does not produce a true p-value in this
case, as genes are not independent of one another, and not all
genes have the same chance of being called differentially
expressed. For that reason, we generate an empirical null
distribution specific to each pair of datasets by permuting group
labels in the two datasets and computing consensus tests from the
resulting randomized data (see Methods for details). The resulting
null distributions are then used to compute empirical p-values for
the hypergeometric score. The results of this analysis are displayed
in Figure 1.
We observe a general lack of consensus, as most datasets pairs
have overlap no greater than what would be expected from
randomized data. Given the diversity of our compendium, we
expect that not all study designs should produce agreement, even
in principle, and we expect outliers as well as groups of studies with
similar designs that would manifest as clusters of high consensus.
However, we do not observe such clusters. In fact, the overall
distribution of empirical p-values is not significantly different from
uniform (KS test p-value = 0.1215). The low overlap of multiple
sclerosis microarray studies has been noted previously [34], and
there are several possible explanations for this finding. There could
in fact be no underlying biological signature that is common to the
various patient cohorts and can be detected in the gene expression
profile of immune cells. The other possibility is that the studies are
simply too noisy relative to the sample size to detect any such
signature.
Although a simple power calculation would dictate that a large
sample size is required to detect what we expect are small
transcriptional alterations in measurements with high variance,
much of this variance may not be due to noisy measurements per
se but may result from variation in genetic background, sample
preparation, and other demographic and technical variables.
Variation that is due to such variables can be largely corrected for
by their explicit inclusion in downstream analysis. For that reason,
most human studies will report demographic information such as
gender and ethnicity. However, other biological variables, such as
Table 1. Datasets included in our MS compendium.
Dataset Platform Factors Tissue
E-MTAB-358 Illumina(HT-12 V3.0) Disease[RRMS(12), PPMS(14), SPMS(16), Control(30)] PBMC
E-MTAB-69 U133-Plus2 Disease[MSrelapse(12), MSremission(14), non-inflamatory(18)] CSF, PBMC
GSE14895 U133A, U133A-2 Disease[CIS(13), Control(4)] PBMC
GSE15245 U133A, U133A-2 Disease[CIS(18), MS(11)] PBMC
GSE16461 U133-Plus2 Disease[MS(8), Control(8)], Cell[CD4,CD8] T cells
GSE17048 Illumina(HT-12 V3.0) Disease[RRMS(36), PPMS(43), SPMS(20), Control(45)] Whole blood
GSE17449 U133A-2 Disease[MS(17), Control(11)], Pregnancy[Yes,No] PBMC
GSE19285 U133-A,B Prognosis[good(17), poor(7)] PBMC
GSE23832 HuGene-1.0st Disease[MS(8), control(4)] PBMC
GSE24427 U133-A,B Prognosis[good(18), poor(7)] PBMC
GSE26484 U133-Plus2 Disease[MS(6),control(4)], Sem4A[low,high] PBMC
GSE26927 Illumina(Ref-8 v2.0) Disease[MS(10), other(10)] Brain
doi:10.1371/journal.pone.0091272.t001
Disease Biomarker Consistency
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detailed genetic information, may be too costly to record and
many of the technical variables are simply unknown; thus, the
resulting variation cannot be modeled directly.
It was recently shown by Leek and Storey that, as such latent
variables affect the expression of many genes at once, they can in
principle be recovered from the dataset correlation structure via a
procedure termed surrogate variable analysis (SVA) [30,35]. This
procedure produces ‘‘surrogate variables’’ that span the space
covered by the latent variables, and can be treated similarly to any
known covariate. Including the surrogate variables in differential
expression analysis can dramatically alter the differential expres-
sion results and the authors demonstrate via a simulation study
that applying SVA produces ranked gene lists that are more stable
across repeated experiments. While SVA has been demonstrated
to have favorable properties in a variety of real data applications,
its rank-stabilizing effect has not been investigated in a practical
setting. Given that the algorithm has the potential to improve
reproducibility in theory, we hypothesized that it is indeed possible
to use SVA as a normalization step when integrating public disease
related studies where a common disease signature may be masked
by dataset specific latent variables that conspire to produce
discordant results.
We applied the SVA algorithm as implemented in the current
Bioconductor version (SVA version 3.6.0) to our MS compendi-
um. Although the ranked list of differentially expressed genes was
significantly altered, no overall improvement in concordance was
observed. In principle, this was not surprising as we expect to see
improvement only in the cases where reproducible signal is
masked by variance induced by latent variables. There is no
guarantee that this condition is met in the MS compendium.
However, upon closer inspection, it became apparent that for
some datasets the SVA algorithm was producing surrogate
variables that had significantly different means within the
experimental groups. Including them in the analysis as covariates
significantly reduced the differential expression signal, thus
producing nearly random gene rankings.
Heterogeneous mixture samples complicate latent
variable estimation
The SVA algorithm is based on the observation that if a gene-
by-sample matrix X arising from a microarray experiment is
modeled as
X~BSzE ð1Þ
where S is the study design matrix (which includes the primary
effect such as disease status as well as any known covariates), the
rows of the residual matrix E are not independent random errors
as is typically assumed, but are correlated. In fact, the data is better
modeled as
X~B’SzCGzU ð2Þ
where G represents the latent variables that explain the residual
correlation of E, and the rows of U are truly independent. The
SVA algorithm is aimed at estimating G by exploiting dataset
correlation structure.
A simple procedure to estimate the latent variable space would
be to perform singular value decomposition (SVD) on the residual
matrix, X{B^S, however this assumes that any latent variables are
completely balanced among the experimental groups, which is not
true in practice. In order to allow latent variables that are non-
orthogonal to the main effect, the algorithm of Leek and Storey
employs a complex iterative procedure, whereby the singular
vectors from the residual SVD are used as initial estimates of G,
Figure 1. Quantifying agreement among multiple sclerosis datasets. Genes are ranked for differential expression by an F-test with respect to
the multiple sclerosis phenotype. The degree of the overlap between lists of the top 5% of differentially expressed genes is evaluated for significance
against a null distribution obtained by permuting the sample labels. The relative significance of the overlap study pairs is indicated by the color scale.
The overall agreement among lists of genes predicted to be associated with multiple sclerosis phenotypes is low.
doi:10.1371/journal.pone.0091272.g001
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and the surrogate variables are recomputed using a reweighting of
the genes in the original data matrix.
The pseudocode for the iterative procedure is as follows:
Require: Gene expression matrix X, design matrix S
1: Estimate k, the dimensionality of the latent variable space
2: Fit model X=BS+E
3: Perform singular value decomposition (SVD) of the residual
X{B^S
4: Set G to the first k eigenvectors {This initial estimate of G is
orthogonal to S}}
5: for i in 1:B{number of iterations} do
6:    C ompute gene weights using the posterior probability that a
G but has no associationwith S
7:    Perform SVD of a weighted matrix
8:    Set G to the first k eigenvectors
9: end for
10: return G
For many studies within our MS compendium this procedure
produced one or two surrogate variables that were heterogeneous,
i.e. showed highly significant differences between groups. While it
is possible that the studies are not well randomized and some
technical variable is correlated with the phenotype of interest in all
of these cases, a detailed investigation revealed a surprising pattern
inconsistent with this conclusion.
The heterogeneous surrogate variables were most pronounced
in the largest and most comprehensive study in our compendium,
GSE17048. Indeed, differentially expressed genes could not be
deconvolved from the latent structure of the dataset; they tended
to be correlated with each other. However, the pattern of
correlation was different from what might be expected if it were
driven by confounding variables. For many differentially expressed
genes the correlation was only observed in the disease state
(Figure 2 A for an illustrative example of group specific
correlation).
Rather than representing non-randomized latent variables we
argue that this effect arises from a more fundamental phenomenon
that is particular to complex tissue samples. Tissue samples
obtained from human subjects tend to vary considerably in their
cell-type composition and this is especially true of human blood
where the proportion of different cell-types can vary four fold in
healthy individuals [36]. Moreover, when assaying mixture
samples we expect that for some genes the expression is altered
in a cell-type specific manner. We believe that this effect in
conjunction with the overall cell type composition variation is
responsible for the unusual correlation structure which in turn
makes SVA difficult to apply.
We model this situation in order to study its impact of
differential expression analysis. For simplicity let us assume that
there are three different cell types and the observed differential
expression is arising from an altered state in one of the cell types.
Figure 2. Disease-specific correlation produces heterogeneous surrogate variables. When SVA is applied to the multiple sclerosis dataset
GSE17048, some of the resulting surrogate variables are unequally distributed among the experimental groups. These surrogate variables (SV) follow
the pattern of disease specific correlation present in this dataset. (A) An example of a correlated pair of top ranked differentially expressed genes. The
group specific correlation coefficients and their significance is noted above the plot: the correlation between these genes is only observed in the
relapse-remitting MS (RRMS) samples. (B) The disease specific pattern of correlation is captured in a surrogate variable. (C) The surrogate variable in
(B) recapitulates the differential expression observed in the individual genes.
doi:10.1371/journal.pone.0091272.g002
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{Methods to do this are described in detail elsewhere [30,35]}
                  gene has an associationwith
Formally, if ei,j denotes the expression of a gene i in cell type j and
pj,k denotes the proportion of cell type j in sample k the expression
measurements can be modeled as
gi,k~ei,1p1,kzei,2p2,kzei,3p3,kzEi,k ð3Þ




for the disease group, where ei,1 represents a disease related
expression state in cell type 1.
If we consider a set of genes that in the control population are
expressed at approximately the same level in all the cell types in
the mixture so that ei,1&ei,2&ei,3, then in the control population
the expression of these genes will be independent of sample-
specific cell type compositions and the series of measurements ~gi
can be modeled as
~gi~eiz~Ei ð5Þ
where ei is the average expression value across the three cell types
and~Ei is random error. Consequently, genes in this category will
not show correlation with each other.
If however, in the disease state, these genes are overexpressed in
a particular cell type, so that we have ei,1&ei,2 and ei,1&ei,3 their
expression values will be dominated by the expression in that




These expression measurements will correlate with the proportion
of the first cell type in each sample,~p1, thereby making the genes
correlate with each other.
In order to demonstrate how this data structure effects
differential expression analysis, we follow the procedure similar
to that outlined in [30] to generate a simulated dataset. We
generate a dataset with two groups and a single artificial latent
variable. Of the 1000 simulated genes, 250 are background noise,
250 have a group effect, 250 are affected by the latent variable,
and 250 are affected by both. However, unlike the procedure in
[30] the baseline expression is modeled not as random values but
as a random mixture of the expression vectors of 3 different cell
types with differential expression arising from an altered expres-
sion state in one of the three cell types (as in equations 3 and 4).
Under this model, we are able to reproduce the group-specific
correlation in the differentially expressed genes (Figure 3B) which
in turn leads the SVA algorithm to estimate a heterogeneous latent
variable (Figure 3C).
In order to remedy this problem, we propose a modification of
the Leek-Storey SVA algorithm which uses a different function to
weight the genes (step 5 in the pseudocode above). The goal of
SVA and related methods can be viewed as partitioning the
variation in the dataset into that which is due to legitimate (and
Figure 3. Performance of different SVA methods in simulated mixture dataset. We simulated a microarray dataset derived from a
heterogeneous mixture of 3 different cell types. The 1000 simulated genes were assigned 4 classes: 250 are background noise (black), 250 have a
group effect (red), 250 are affected by an artificial latent variable (blue), and 250 are affected by both (green). The group effect is modeled as
differential expression in one of the three cell types. (A) Heatmap of an example dataset with gene class denoted in the color on the right. Aside from
the structure imposed by the group effect and the linear latent variable both affecting 500 genes the dataset has global correlation structure,
imposed by the mixture model. (B) Under this model we are able to recapitulate the group specific correlation in the differentially expressed genes
that we observe in real datasets, see example in Figure 2. (C) Applying SVA to the simulated datasets produces surrogate variables that are strongly
correlated with the experimental group. (D) Boxplot representing distribution of AUCs, area under receiver operating characteristic curve, for
discriminating the green differentially expressed genes from the blue and black sets resulting from 20 repeats of the simulation. While the original
SVA algorithm does not perform well in this simulation, the modified algorithm is robust to the confounding latent structure.
doi:10.1371/journal.pone.0091272.g003
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thus reproducible) difference between the clinical groups and that
which is due to latent variables (which may be confounded with
the group effect). This is accomplished by computing SVD on a
reweighted matrix and the original approach is to use local FDR
as the posterior probability that a gene is affected by latent
variables, G, and is not affected by the primary group effect. While
this approach is statistically grounded, it does not work well on
mixture datasets, as the posterior probabilities eventually converge
to values near 1 thus weighting most genes similarly. In this case
surrogate vectors approximate the eigenvectors of the unweighted
SVD and thus capture all the variation in the dataset, including
the differential expression. While this is desirable in cases when the
groups are not randomized with respect to some technical or
biological variable, this becomes problematic in complex mixture
samples where differential expression may be confounded with the
correlation structure even under perfect randomization. Though
variations of the original SVA method have been proposed, most
notably SVA-PLS [37] and ISVA [38], they do not address this
aspect of latent variable estimation and perform no better on the
simulated mixture dataset (see Figure S1)
We propose an alternative weighing approach that is less
aggressive. In place of the posterior probability our approach uses
the raw p-value for both the primary and the latent effects. In
doing so we are not equating the p-values with posterior
probability but rather using them as an alternative gene-weighing
scheme which has the effect of restricting the degree to which
surrogate vectors can vary among the clinical groups. We compute
the p-value via a permutation test, since in real datasets we observe
genes that do not conform to a normal distribution. Using the p-
value directly has the effect of generating surrogate variables that
only show association with the primary effect that might be
expected by chance alone in a completely randomized study. The
resulting surrogate vectors are thus still allowed to be non-
orthogonal and may in fact show large deviations from orthog-
onality if the sample size is small however this approach prevents
the generation of surrogate variables with significantly different
group means. While this method will not fully recover the correct
latent structure when studies are not well randomized, it is able to
handle correlation that is induced by interaction with the primary
variable, as is the case in mixture samples.
To illustrate the effect of our approach, we apply the different
methods to the simulation described above. SVA should in
principle increase our power to detect the 250 differentially
expressed genes that are also affected by the artificial latent
variable. Because in this simulation the correlation structure of the
data is complex, and includes correlation induced by the mixture
model itself, the SVA algorithm produces multiple surrogate
variables some of which have significantly different within group
means and the intended effect of SVA is canceled out. Our
modification, however, is robust to this effect and, as intended, is
able to improve the detection of differentially expressed genes
(Figure 3D).
Modified SVA* algorithm successfully improves inter-
study agreement
Using the modified SVA* algorithm we were able to achieve
a significant improvement in dataset concordance within our
MS compendium, confirming our initial hypothesis that latent
variable modeling can be effective in a meta-analysis context.
The method is applied to each dataset independently, and it
doubles the number of significant pairwise overlaps between
sets of differentially expressed genes over what is produced by
standard differential expression analysis (Figure 4). The
modified SVA* algorithm also produces much better agree-
ment than the original SVA algorithm, demonstrating that our
modification to the weighting function is crucial to achieving
the desired effect.
Since we demonstrate that the weighting function and heavily
biased surrogate vectors are indeed the problem, it is natural to
investigate how the algorithm would perform with no weighting at
all. Leek and Storey reject this approach of using the initial
orthogonal surrogate variable estimates. While they believe it
would be effective at correcting for latent structure, it produces
anti-conservative p-values. In our study we are not concerned with
p-values, but rather with gene ranking; nevertheless, we find that
the orthogonal method is not effective at improving dataset
concordance, demonstrating that some variation of the weighting
approach, which allows surrogate variables to correlate with
clinical variables, is required in order to observe improvement in
agreement.
We have demonstrated that our modified SVA approach is
effective at improving overall dataset agreement. However, the
particular pattern of agreement (Figure 5) gives us further
confidence that this improvement is biologically meaningful.
While the naive approach produces agreement that barely
deviates from what is expected by chance, with pairs of
agreeing datasets seemingly randomly distributed, the modified
SVA approach reveals a cluster of highly overlapping studies.
Importantly, several of the studies that cluster together are
studies that are a priori expected to be of high quality because
they have large sample sizes. The clustering is also indepen-
dent of platform, which further supports its biological
relevance.
Figure 4. Comparisons of the inter-study agreement generated
by various SVA algorithms. For each p-value threshold we plot the
number of pairwise comparisons (out of 120 possible) reaching that
level of significance. SVA* produces the most comparisons with small p-
values. The overall differences between the agreement curves plotted
were evaluated using a single tailed signed rank test on the log
transformed empirical p-values which evaluates the hypothesis that
SVA* improves the significance of individual pairwise comparisons.
Overall agreement using the modified SVA algorithm was significantly
improved over the uncorrected analysis (p = 0.015) and the Leek-Storey
SVA (p = 0.022).
doi:10.1371/journal.pone.0091272.g004
Disease Biomarker Consistency
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The modified SVA* algorithm also improves inter study
agreement in an independent compendium of
Parkinson’s disease datasets
While our modified SVA algorithm was developed from basic
considerations and we did not perform any parameter fitting or
optimizations, our approach was informed by a detailed investi-
gation of the datasets in our MS compendium. In order to confirm
that the proposed SVA* algorithm can be useful in multiple
contexts we use the algorithm without modification on an
independent gene expression compendium of PD datasets. This
compendium comprises publicly available datasets used in a recent
Parkinson’s meta-analysis [39], and differs significantly from our
MS compendium. Most of the datasets in the Parkinson’s
compendium use brain samples, with many from the regions
directly affected by neuron loss (Table 2), and are thus studying the
tissue where macroscopic disease pathology can be observed.
Thus, we expect that the disease signal should be considerably
larger which in turn should lead to better inter-dataset correspon-
dence. Indeed, we find that unlike in the MS compendium, the
baseline uncorrected correspondence is appreciably better than
random.
We expect that the agreement can be improved further with an
application of latent variable correction. However, like blood,
brain tissue is a complex mixture of multiple cell types and
heterogeneity in relative cell proportions may be exaggerated in
the disease state [39,40]. Hence, brain samples can produce the
same kind of confounded correlation structure that interferes with
latent variable correction making our modified SVA algorithm
particularly useful.
As is the case with the MS compendium, no improvement is
observed with the original, Leek-Storey, SVA algorithm. Howev-
er, confirming our expectations, the modified SVA* algorithm is
able to significantly improve the inter-dataset concordance
producing a greater number of comparisons with small p-values
(see Figure 6).
Unlike multiple sclerosis PD is a disease for which concrete
molecular mechanisms are established, making it possible to
evaluate the results from a biological rather than statistical point of
view. For example, SNCA, a gene whose product is known to be
directly involved in disease pathology is downregulated in many of
the datasets (ranked in the top 10% for 7 out of the 14 datasets)
and applying SVA* improves its overall ranking (SNCA is 5th
instead of 11th in mean rank). One interesting observation is that
SVA* is particularly effective at improving the agreement of a
whole blood dataset GSE6316 (which we expect is subject to large
cell proportion variation) with datasets that assayed brain tissue.
Changes in the expression of SNCA can be observed in this blood
dataset even without any correction but applying SVA* shifts
SNCA differential expression ranking from 139 to 34 (out of 9062
evaluated genes). On the other hand using Leek-Storey SVA
SNCA is ranked 3312, further corroborating our hypothesis that
the original SVA algorithms is most compromised in mixture
datasets with large proportion variation.
Discussion
Given that reproducibility in microarray studies with human
subjects is a recognized problem, alternative analysis methods that
are capable of resolving disagreements are of great interest.
Improved concordance would provide independent validation for
findings of individual studies, improve our ability to do meta-
analysis, and provide more trustworthy predictions regarding
differentially expressed genes. Moreover, inter-study concordance
presents a unique evaluation for the analysis methods themselves.
Improved agreement, when carefully evaluated against permuted
datasets, must be achieved by extracting more biologically
meaningful information from the data. For example, it has been
Figure 5. Heatmap of inter-study agreement after modified SVA correction. We observe dramatic agreement over a simple F-test using
explicitly provided covariates only (uncorrected) as well as the unmodified SVA.
doi:10.1371/journal.pone.0091272.g005
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shown that pathway level analysis, which can improve power of
individual studies, also improves the agreement among indepen-
dent datasets [8].
We present a method that is able to achieve improvement in
agreement through estimating and modeling latent variables. Our
method builds on surrogate variable analysis, a previously
described approach for latent variable estimation. However, we
demonstrate that unique correlation structure present in complex
mixture samples can compromise the effectiveness of SVA, and we
propose a robust alternative that overcomes this problem. The fact
that improvement in agreement could only be observed with the
modified SVA* algorithm highlights the importance of under-
standing the correlation structure in detail. Further work is needed
to determine whether additional improvements in SVA can be
achieved, and whether other modifications will be necessary for
different types of datasets. Currently SVA operates without any
knowledge of gene identities and as such differentiating between
confounded latent variables and correlation structure that is due to
a legitimate biological phenomenon may not always be possible. It
is likely that approaches that use control genes, such as one
described in reference [41], can be combined with unsupervised
SVD based techniques to achieve superior results.
Despite the potential for further improvements, our study has
demonstrated that latent variable modeling can be used as an
effective out-of-the-box pre-processing approach in integrating
human disease datasets and thus can be applied effectively to
Table 2. Datasets included in our Parkinson’s compendium.
Dataset Platfrom Tissue Samples(PD/controls)
GSE22491 Agilent(G4112F) PBMCs 8/10
GSE20159 Illumina(HT-12 V3.0) Brain, substantia nigra 16/17
GSE20141 U133-Plus2 Brain, substantia nigra 8/10
GSE20146 U133-Plus2 Brain, globus pallidus interna 8/10
GSE20163 U133A Brain, substantia nigra 10/10
GSE20164 U133A Brain, substantia nigra 9/8
GSE20168 U133A Brain, prefrontal cortex 15/14
GSE20291 U133A Brain, putamen 20/15
GSE20292 U133A Brain, substantia nigra 18/11
GSE20314 U133A Brain, cerebellum 4/4
GSE8397 U133A Brain, substantia nigra 18/29
GSE7307 U133-Plus2 Brain (multiple) 182/26
GSE7621 U133-Plus2 Brain, substantia nigra 9/16
GSE6613 U133A Whole blood 22/50
doi:10.1371/journal.pone.0091272.t002
Figure 6. Improvement in inter-study agreement in the Parkinson’s compendium. Comparisons of the inter-study agreement generated
by various SVA algorithms. For each p-value threshold we plot the number of pairwise comparisons (out of 91 possible) reaching that level of
significance. The overall differences between the agreement curves plotted were evaluated using a single tailed signed rank test on the log
transformed empirical p-values. Overall agreement using the modified SVA algorithm was significantly improved over the uncorrected analysis
(p = 6.8?1026) and the Leek-Storey SVA (p = 1.8?1024).
doi:10.1371/journal.pone.0091272.g006
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Expression data and associated information was downloaded
from GEO or ArrayExpress. Affymetrix data was processed using
GCRMA. Illumina data was background adjusted with the
bg.adjust() function from the ‘‘affy’’ BioConductor package, log-
transformed, and quantile normalized. Data for the Agilent
dataset, GSE22491, was downloaded from GEO in the processed
format supplied by the authors. Probes were mapped to gene
names using GEO GPL files and when several probes mapped to
the same gene, the one with the maximum mean expression was
kept as the representative. The number of genes before filtering
varied from 13000 to 20000 depending on platform. The bottom
20% of genes with low expression or low variance were removed
from each dataset before processing for differential expression.
Using these criteria approximately 25% of the genes are filtered
out since low expression and low variance genes largely overlap.
Differential expression was evaluated with an F-statistic comparing
a model that includes the disease related phenotype with one that
includes only covariates. The covariates included gender and other
experimental covariates provided by the authors (see Table 1).
Corrected differential expression lists were produced by appending
surrogate variables computed with various modifications of SVA
to the design matrices.
Overlap Computation
Our goal for the overlap computation was to evaluate
consistency of gene rankings while taking into account that the
number of differentially expressed genes is small and therefore
ranking in the bottom of the list is not biologically meaningful.
Thus, we evaluate the extent of nonrandom overlap in the top 5%
of differentially expressed genes from each dataset. We compute
raw pairwise overlap values as the hypergeometric probability p(k,
m, n, N) where m and n are the number of genes in the candidate
list of each dataset that was also present in the other dataset, k is
the number of genes present in the overlap, and N is the total
number of genes present in both datasets after filtering.
Null distributions of the raw overlap score were generated by
permuting the phenotype labels of each dataset (while keeping
covariates the same) and applying the differential expression
pipelines to the permuted labels. For each dataset we generated 20
permutation based gene rankings and these were used to generate
400 dataset pair specific null overlap scores. Each dataset pair
generates a unique null distribution with some being close to
uniform while others are skewed towards small p-values due to
gene-wise dependence. By comparing the real hypogeometric
value to this distribution we arrive at an empirical p-value that
corresponds to the amount of agreement we might expect by
chance alone. We include a R script that applies this analysis to
simulated mixture datasets in the supplement (File S1).
Simulations
Our simulation is based on that described in Leek and Storey
[30] with the alteration that the baseline expression of each gene
(the expression unaffected by the latent variable or the group
effect) is modeled not as independent random values but as a
random mixture of 3 expression vectors representing pure cell
types. The vectors are added in linear expression space and the
data is subsequently logged. The dataset is divided in half to
represent two experimental groups. Overexpression in the
‘‘disease’’ group is simulated by altering 500 genes in one of the
pure cell expression vectors. We also model a artificial, that is
distinct from those induced by the mixture model, latent variable
as a random vector drawn from a uniform distribution. The gene
specific effects for the latent variable are then drawn from a
normal distributions and the outer products of the effect vector
with the latent variable is added to the expression matrix. Finally,
random noise is added to create the final matrix. The dataset was
evaluated for differential expression using a T-test with no
covariates and a T-test with covariates generated by the original
SVA algorithm and our modified version. All the code necessary to
run the simulation and reproduce Figure 3 is provided in the
supplement (File S1).
Supporting Information
Figure S1 Performance of original Leek-Storey SVA and
alternatives on a mixture dataset with cell type specific
regulation Simulation in Figure 3 was repeated with other SVA
alternatives. Neither SVA-PLS or ISVA address the complex
correlation structure of mixture datasets and do not improve
differential expression discovery.
(TIF)
File S1 Source code for modified SVA and simulations.
(ZIP)
Acknowledgments
We would to thank Patrick Bradley, Yongchao Ge, and Elena Zaslavsky for
helpful comments and suggestions.
Author Contributions
Conceived and designed the experiments: MC SS. Performed the
experiments: MC. Analyzed the data: MC. Wrote the paper: MC SS.
References
1. Borozan I, Chen L, Paeper B, Heathcote JE, Edwards AM, et al. (2008) Maid :
an effect size based model for microarray data integration across laboratories
and platforms. BMC Bioinformatics 9: 305.
2. Choi H, Shen R, Chinnaiyan AM, Ghosh D (2007) A latent variable approach
for meta-analysis of gene expression data from multiple microarray experiments.
BMC Bioinformatics 8: 364.
3. Choi JK, Yu U, Kim S, Yoo OJ (2003) Combining multiple microarray studies
and modeling interstudy variation. Bioinformatics 19 Suppl 1: i84–i90.
4. Stevens JR, Doerge RW (2005) Combining affymetrix microarray results. BMC
Bioinformatics 6: 57.
5. Breitling R, Armengaud P, Amtmann A, Herzyk P (2004) Rank products: a
simple, yet powerful, new method to detect differentially regulated genes in
replicated microarray experiments. FEBS Lett 573: 83–92.
6. Kotelnikova E, Shkrob MA, Pyatnitskiy MA, Ferlini A, Daraselia N (2012)
Novel approach to metaanalysis of microarray datasets reveals muscle
remodeling-related drug targets and biomarkers in duchenne muscular
dystrophy. PLoS Comput Biol 8: e1002365.
7. Arasappan D, Tong W, Mummaneni P, Fang H, Amur S (2011) Meta-analysis
of microarray data using a pathway-based approach identifies a 37-gene
expression signature for systemic lupus erythematosus in human peripheral
blood mononuclear cells. BMC Med 9: 65.
8. Manoli T, Gretz N, Grne HJ, Kenzelmann M, Eils R, et al. (2006) Group testing
for pathway analysis improves comparability of different microarray datasets.
Bioinformatics 22: 2500–2506.
9. Ein-Dor L, Kela I, Getz G, Givol D, Domany E (2005) Outcome signature genes
in breast cancer: is there a unique set? Bioinformatics 21: 171–178.
10. Zhang M, Zhang L, Zou J, Yao C, Xiao H, et al. (2009) Evaluating
reproducibility of differential expression discoveries in microarray studies by
considering correlated molecular changes. Bioinformatics 25: 1662–1668.
Disease Biomarker Consistency
PLOS ONE | www.plosone.org 9 April 2014 | Volume 9 | Issue 4 | e91272
11. Tseng GC, Ghosh D, Feingold E (2012) Comprehensive literature review and
statistical considerations for microarray meta-analysis. Nucleic Acids Res 40:
3785–3799.
12. Eysenck HJ (1995) Meta-analysis of best-evidence synthesis? J Eval Clin Pract 1:
29–36.
13. Eysenck HJ (1994) Meta-analysis and its problems. BMJ 309: 789–792.
14. Kang DD, Sibille E, Kaminski N, Tseng GC (2012) Metaqc: objective quality
control and inclu- sion/exclusion criteria for genomic meta-analysis. Nucleic
Acids Res 40: e15.
15. Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, et al. (2010)
Ontology-based metaanalysis of global collections of high-throughput public
data. PLoS One 5.
16. Kapushesky M, Emam I, Holloway E, Kurnosov P, Zorin A, et al. (2010) Gene
expression atlas at the european bioinformatics institute. Nucleic Acids Res 38:
D690–D698.
17. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. (2001)
Recommended diagnostic criteria for multiple sclerosis: guidelines from the
international panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121–
127.
18. Achiron A, Grotto I, Balicer R, Magalashvili D, Feldman A, et al. (2010)
Microarray analysis identifies altered regulation of nuclear receptor family
members in the pre-disease state of multiple sclerosis. Neurobiol Dis 38: 201–
209.
19. Annibali V, Ristori G, Angelini DF, Serafini B, Mechelli R, et al. (2011)
Cd161(high)cd8+t cells bear pathogenetic potential in multiple sclerosis. Brain
134: 542–554.
20. Bomprezzi R, Ringnr M, Kim S, Bittner ML, Khan J, et al. (2003) Gene
expression profile in multiple sclerosis patients and healthy controls: identifying
pathways relevant to disease. Hum Mol Genet 12: 2191–2199.
21. Gandhi KS, McKay FC, Cox M, Riveros C, Armstrong N, et al. (2010) The
multiple sclerosis whole blood mrna transcriptome and genetic associations
indicate dysregulation of specific t cell pathways in pathogenesis. Hum Mol
Genet 19: 2134–2143.
22. Gilli F, Lindberg RLP, Valentino P, Marnetto F, Malucchi S, et al. (2010)
Learning from nature: pregnancy changes the expression of inammation-related
genes in patients with multiple sclerosis. PLoS One 5: e8962.
23. Gurevich M, Tuller T, Rubinstein U, Or-Bach R, Achiron A (2009) Prediction
of acute multiple sclerosis relapses by transcription levels of peripheral blood
cells. BMC Med Genomics 2: 46.
24. Hecker M, Goertsches RH, Fatum C, Koczan D, Thiesen HJ, et al. (2012)
Network analysis of transcriptional regulation in response to intramuscular
interferon-beta-1a multiple sclerosis treatment. Pharmacogenomics J 12: 360.
25. Riveros C, Mellor D, Gandhi KS, McKay FC, Cox MB, et al. (2010) A
transcription factor map as revealed by a genome-wide gene expression analysis
of whole-blood mrna transcriptome in multiple sclerosis. PLoS One 5: e14176.
26. ichi Satoh J, Nakanishi M, Koike F, Onoue H, Aranami T, et al. (2006) T cell
gene expression profiling identifies distinct subgroups of japanese multiple
sclerosis patients. J Neuroimmunol 174: 108–118.
27. Zhang F, Shi Y, Wang L, Sriram S (2011) Role of hdac3 on p53 expression and
apoptosis in t cells of patients with multiple sclerosis. PLoS One 6: e16795.
28. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, et al. (2010) T
helper type 1 and 17 cells determine efficacy of interferon-beta in multiple
sclerosis and experimental encephalomyelitis. Nat Med 16: 406–412.
29. Bushnell SE, Zhao Z, Stebbins CC, Cadavid D, Buko AM, et al. (2012) Serum il-
17f does not predict poor response to im ifnbeta-1a in relapsing-remitting ms.
Neurology 79: 531–537.
30. Leek JT, Storey JD (2007) Capturing heterogeneity in gene expression studies by
surrogate variable analysis. PLoS Genet 3: 1724–1735.
31. Goldenberg MM (2012) Multiple sclerosis review. P T 37: 175–184.
32. Lu S, Li J, Song C, Shen K, Tseng GC (2010) Biomarker detection in the
integration of multiple multi-class genomic studies. Bioinformatics 26: 333–340.
33. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, et al. (2005) Multiple-
laboratory comparison of microarray platforms. Nat Methods 2: 345–350.
34. Hecker M, Paap BK, Goertsches RH, Kandulski O, Fatum C, et al. (2011)
Reassessment of blood gene expression markers for the prognosis of relapsing-
remitting multiple sclerosis. PLoS One 6: e29648.
35. Leek JT, Storey JD (2008) A general framework for multiple testing dependence.
Proc Natl Acad Sci U S A 105: 18718–18723.
36. Abbas AR, Wolslegel K, Seshasayee D, Modrusan Z, Clark HF (2009)
Deconvolution of blood microarray data identifies cellular activation patterns in
systemic lupus erythematosus. PLoS One 4: e6098.
37. Chakraborty S, Datta S, Datta S (2012) Surrogate variable analysis using partial
least squares (sva-pls) in gene expression studies. Bioinformatics 28: 799–806.
38. Teschendorff AE, Zhuang J, Widschwendter M (2011) Independent surrogate
variable analysis to deconvolve confounding factors in large-scale microarray
profiling studies. Bioinformatics 27: 1496–1505.
39. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, et al. (2010) Pgc-1, a
potential therapeutic target for early intervention in parkinson’s disease. Sci
Transl Med 2: 52ra73.
40. Kuhn A, Thu D, Waldvogel HJ, Faull RLM, Luthi-Carter R (2011) Population-
specific expression analysis (psea) reveals molecular changes in diseased brain.
Nat Methods 8: 945–947.
41. Gagnon-Bartsch JA, Speed TP (2012) Using control genes to correct for
unwanted variation in microarray data. Biostatistics 13: 539–552.
Disease Biomarker Consistency
PLOS ONE | www.plosone.org 10 April 2014 | Volume 9 | Issue 4 | e91272
